Cargando…

Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis

BACKGROUND: 5-Alpha-reductase inhibitors (5-ARIs) have been suggested as potential chemopreventive agents for prostate cancer (PCa). This study was conducted to evaluate the effect of 5-ARIs on the incidence and mortality of PCa. METHODS: The PubMed, Embase and Cochrane Library databases were search...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xu, Wang, Yao-Hui, Yang, Zhi-Qiang, Shao, Yan-Xiang, Yang, Wei-Xiao, Li, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807305/ https://www.ncbi.nlm.nih.gov/pubmed/33457226 http://dx.doi.org/10.21037/tau-20-843

Ejemplares similares

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
por: Foldes, Cara A., et al.
Publicado: (2020)

Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis
por: Luo, Lian-Min, et al.
Publicado: (2019)

5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
por: Wang, Ziting, et al.
Publicado: (2023)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer
por: Hudak, Steven J, et al.
Publicado: (2006)

5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

5-alpha-reductase and the development of the human prostate
por: Radmayr, C., et al.
Publicado: (2008)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
por: Deng, Tuo, et al.
Publicado: (2020)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
por: Kim, Jae Heon, et al.
Publicado: (2020)

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
por: Falagario, Ugo G., et al.
Publicado: (2023)

5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
por: Wang, Jiamin, et al.
Publicado: (2018)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
por: Ayodele, Olulade, et al.
Publicado: (2021)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Is Transforming Growth Factor-β Signaling Activated in Human Hypertrophied Prostate Treated by 5-Alpha Reductase Inhibitor?
por: Kim, Hye Kyung, et al.
Publicado: (2013)

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
por: Kumar, Abhishek, et al.
Publicado: (2019)

Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
por: Escamilla-Cruz, Mariana, et al.
Publicado: (2023)

Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications
por: Wang, Kai, et al.
Publicado: (2014)

The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
por: Azizi, Aziemah, et al.
Publicado: (2021)

Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013)

Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
por: Choi, Gwang Seong, et al.
Publicado: (2016)

Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative
por: Loloi, Justin, et al.
Publicado: (2022)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

Use of 5-Alpha-Reductase Inhibitors Did Not Increase the Risk of Cardiovascular Diseases in Patients with Benign Prostate Hyperplasia: A Five-Year Follow-Up Study
por: Hsieh, Teng-Fu, et al.
Publicado: (2015)

May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
por: Adamowicz, Jan, et al.
Publicado: (2020)

5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec
por: Lin, Wenhsu, et al.
Publicado: (2017)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men
por: Chang, Jooyoung, et al.
Publicado: (2019)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer
por: Delgado-Balderas, Jesus Rolando, et al.
Publicado: (2020)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_shh4b291or46gq13f0i55a3ki1